Karus Therapeutics announces dosing of first patients with KA2237 in clinical study

Karus Therapeutics, a company into the development of innovative, orally active medicines with breakthrough potential in the treatment of cancer, has announced that the first patients have been dosed in a Phase I study for its lead candidate, KA2237.

Source: Drug Development Technology - October 6, 2016 Category: Pharmaceuticals Source Type: news